Bio­gen be­gins lay­ing off staff as it con­tin­ues to push its new Alzheimer's drug

The lay­offs at Bio­gen have be­gun.

In the wake of a con­tro­ver­sial ap­proval for its Alzheimer’s drug Aduhelm, Bio­gen start­ed in­form­ing em­ploy­ees Wednes­day that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.